Trial intelligence / Profile preview

First-line anlotinib plus dacomitinib or almonertinib in EGFR-mutated NSCLC (real-world)

ChiCTR2100051378Phase 4Not yet recruiting

Sponsor

First Affiliated Hospital of Kunming Medical University

Start

Sep 2021

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1